45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
25,989
Insurances with rates
7
CPT / HCPCS codes
4,009
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 73554-1111-1 | LOVOTIBEGLOGENE AUTOTEMCEL 1.7 X 10EXP6 TO 20 X 10EXP6 CELL/ML IV SUSP | $15,500,000 | $8,060,000 | — | — | 6 |
| 73554-3111-1 | BETIBEGLOGENE AUTOTEMCEL 2 X 10EXP6 TO 20 X 10EXP6 CELL/ML IV SUSP | $14,000,000 | $7,280,000 | — | — | 6 |
| 51167-290-01 | EXAGAMGLOGENE AUTOTEMCEL 4 X 10EXP6 TO 13 X 10EXP6 CELL/ML IV SUSP | $11,000,000 | $5,720,000 | — | — | 6 |
| 51167-290-09 | EXAGAMGLOGENE AUTOTEMCEL 4 X 10EXP6 TO 13 X 10EXP6 CELL/ML IV SUSP | $11,000,000 | $5,720,000 | — | — | 6 |
| 60923-502-11 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-503-12 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-509-18 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-510-19 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-512-21 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-514-23 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-518-27 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-519-28 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-520-29 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-521-30 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-524-33 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-526-35 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-532-41 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-534-43 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-536-45 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-537-46 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-540-49 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-559-68 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-561-70 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-501-10 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-504-13 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-505-14 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-506-15 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-507-16 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-508-17 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-511-20 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-513-22 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-515-24 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-516-25 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-517-26 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-522-31 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-523-32 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-525-34 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-527-36 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-528-37 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-529-38 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-530-39 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-531-40 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-533-42 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-535-44 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-538-47 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-539-48 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-541-50 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-542-51 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-543-52 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
| 60923-544-53 | DELANDISTROGENE MOXEPARVOVEC-ROKL 1.33X10EXP13 VG/ML INTRAVENOUS SUSP | $4,800,000 | $2,496,000 | — | — | 6 |
Showing top 50 of 25,989 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.